Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Discussion on the ADAURA study

David Spigel • 28 May 2020
ASCO 2020
Lung Cancer Non-Small Cell Lung Cancer Osimertinib
ADAURA

David R. Spigel, MD, FASCO, Sarah Cannon Research Institute, Nashville, TN, discusses the ADAURA study (NCT02511106) data presented at ASCO 2020. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from David Spigel

2:00
Lung cancer updates at ASCO 2021
David Spigel • 26 May 2021
4:46
5-year survival outcomes from the PACIFIC trial
David Spigel • 26 May 2021
3:37
CANOPY-A: canakinumab for early stage NSCLC
David Spigel • 28 May 2020
2:31
RESILIENT: liposomal irinotecan in relapsed SCLC
David Spigel • 28 May 2020

Related Videos

0:37
STABLE-MATES: sublobar resection vs SAbR in high-risk patients with stage I NSCLC
Clive Peedell • 18 Apr 2024
0:44
BTOG 2024: networking highlights and insights
Clive Peedell • 18 Apr 2024
0:49
Ongoing trials in thoracic radiotherapy: evaluating current role and significance
Thomas Newsom-Davis • 18 Apr 2024
4:20
Insights from BTOG 2024: advancements in TNM Staging, systematic staging, & immunotherapy strategies
Thomas Newsom-Davis • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals